Cargando…

Effectiveness and Adherence of Dry Eye Patients Who Switched from Short- to Long-Acting Diquafosol Ophthalmic Solution

Long-acting (lasting extend) diquafosol ophthalmic solution 3% (DQSLX) is administered three times daily versus six times daily for the currently approved diquafosol ophthalmic solution (DQS). We investigated the efficacy and adherence of switching from DQS to DQSLX in patients with dry eye disease....

Descripción completa

Detalles Bibliográficos
Autores principales: Ishikawa, Sho, Sasaki, Takanori, Maruyama, Takahumi, Murayama, Koichiro, Shinoda, Kei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342394/
https://www.ncbi.nlm.nih.gov/pubmed/37445527
http://dx.doi.org/10.3390/jcm12134495
_version_ 1785072488620752896
author Ishikawa, Sho
Sasaki, Takanori
Maruyama, Takahumi
Murayama, Koichiro
Shinoda, Kei
author_facet Ishikawa, Sho
Sasaki, Takanori
Maruyama, Takahumi
Murayama, Koichiro
Shinoda, Kei
author_sort Ishikawa, Sho
collection PubMed
description Long-acting (lasting extend) diquafosol ophthalmic solution 3% (DQSLX) is administered three times daily versus six times daily for the currently approved diquafosol ophthalmic solution (DQS). We investigated the efficacy and adherence of switching from DQS to DQSLX in patients with dry eye disease. We retrospectively enrolled 54 patients (17 men and 37 women) with eye drop prescription changes from DQS to DQSLX between December 2022 and March 2023. The number of eye drops, subjective symptoms, tear breakup time (TBUT), and fluorescein staining scores from baseline to 4 weeks after starting DQSLX were evaluated. Participants then chose between DQSLX and DQS. Patients administered DQSLX three times per day, as listed on the package insert, 88.9% of the time; significantly higher than the 5.6% of patients who used DQS six times per day, as instructed. The DQSLX group showed significant improvements in symptoms and fluorescein staining scores (23.3 ± 20.1 and 0.8 ± 1.7, respectively) compared with the baseline (37.8 ± 24.1 and 1.1 ± 1.5, p = 0.01 and <0.001, respectively). The TBUT in the DQSLX group (5.0 ± 2.5 s) did not significantly improve compared to the DQS group (4.5 ± 1.7 s) (p = 0.75). Fifty-one (94.4%) patients opted to continue DQSLX because of the pleasant feeling of the eye drops, long-lasting moisture, and less frequent administration. The efficacy and adherence of DQSLX was comparable to DQS.
format Online
Article
Text
id pubmed-10342394
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103423942023-07-14 Effectiveness and Adherence of Dry Eye Patients Who Switched from Short- to Long-Acting Diquafosol Ophthalmic Solution Ishikawa, Sho Sasaki, Takanori Maruyama, Takahumi Murayama, Koichiro Shinoda, Kei J Clin Med Article Long-acting (lasting extend) diquafosol ophthalmic solution 3% (DQSLX) is administered three times daily versus six times daily for the currently approved diquafosol ophthalmic solution (DQS). We investigated the efficacy and adherence of switching from DQS to DQSLX in patients with dry eye disease. We retrospectively enrolled 54 patients (17 men and 37 women) with eye drop prescription changes from DQS to DQSLX between December 2022 and March 2023. The number of eye drops, subjective symptoms, tear breakup time (TBUT), and fluorescein staining scores from baseline to 4 weeks after starting DQSLX were evaluated. Participants then chose between DQSLX and DQS. Patients administered DQSLX three times per day, as listed on the package insert, 88.9% of the time; significantly higher than the 5.6% of patients who used DQS six times per day, as instructed. The DQSLX group showed significant improvements in symptoms and fluorescein staining scores (23.3 ± 20.1 and 0.8 ± 1.7, respectively) compared with the baseline (37.8 ± 24.1 and 1.1 ± 1.5, p = 0.01 and <0.001, respectively). The TBUT in the DQSLX group (5.0 ± 2.5 s) did not significantly improve compared to the DQS group (4.5 ± 1.7 s) (p = 0.75). Fifty-one (94.4%) patients opted to continue DQSLX because of the pleasant feeling of the eye drops, long-lasting moisture, and less frequent administration. The efficacy and adherence of DQSLX was comparable to DQS. MDPI 2023-07-05 /pmc/articles/PMC10342394/ /pubmed/37445527 http://dx.doi.org/10.3390/jcm12134495 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ishikawa, Sho
Sasaki, Takanori
Maruyama, Takahumi
Murayama, Koichiro
Shinoda, Kei
Effectiveness and Adherence of Dry Eye Patients Who Switched from Short- to Long-Acting Diquafosol Ophthalmic Solution
title Effectiveness and Adherence of Dry Eye Patients Who Switched from Short- to Long-Acting Diquafosol Ophthalmic Solution
title_full Effectiveness and Adherence of Dry Eye Patients Who Switched from Short- to Long-Acting Diquafosol Ophthalmic Solution
title_fullStr Effectiveness and Adherence of Dry Eye Patients Who Switched from Short- to Long-Acting Diquafosol Ophthalmic Solution
title_full_unstemmed Effectiveness and Adherence of Dry Eye Patients Who Switched from Short- to Long-Acting Diquafosol Ophthalmic Solution
title_short Effectiveness and Adherence of Dry Eye Patients Who Switched from Short- to Long-Acting Diquafosol Ophthalmic Solution
title_sort effectiveness and adherence of dry eye patients who switched from short- to long-acting diquafosol ophthalmic solution
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342394/
https://www.ncbi.nlm.nih.gov/pubmed/37445527
http://dx.doi.org/10.3390/jcm12134495
work_keys_str_mv AT ishikawasho effectivenessandadherenceofdryeyepatientswhoswitchedfromshorttolongactingdiquafosolophthalmicsolution
AT sasakitakanori effectivenessandadherenceofdryeyepatientswhoswitchedfromshorttolongactingdiquafosolophthalmicsolution
AT maruyamatakahumi effectivenessandadherenceofdryeyepatientswhoswitchedfromshorttolongactingdiquafosolophthalmicsolution
AT murayamakoichiro effectivenessandadherenceofdryeyepatientswhoswitchedfromshorttolongactingdiquafosolophthalmicsolution
AT shinodakei effectivenessandadherenceofdryeyepatientswhoswitchedfromshorttolongactingdiquafosolophthalmicsolution